Investigators developed the test for early detection of Barrett's esophagus that offers promise for preventing deaths from esophageal adenocarcinoma. The test involves a novel swallowable balloon device that samples the esophagus and a DNA assay that detects Barrett's esophagus and esophageal cancers. In a major step to bringing this technology forward to patients, the balloon device has just received 510K clearance from the US FDA for clinical use.
Enable Injections, Inc., a company developing and manufacturing investigational wearable infusion devices for combination products, today announced it has entered into a development agreement with Genentech, a member of the Roche Group. The enFuse™, under development by Enable, will enable patient-administered subcutaneous delivery of high-volume therapeutics.
Now seven months along, the webinar series that Science and Fondation Ipsen launched in January 2019 -- to openly address topics many people believe scientists should be evaluating more critically -- is having the hoped-for impact.
Scientists from NUST MISIS together with colleagues from Lomonosov Moscow State University have developed a method for quick and effective analysis of the composition of water, which will help to solve the problem of industrial pollution. The methodology is based on the use of environmentally friendly nanoparticles with fluorescent properties. The method is also suitable for hard-to-reach or remote sources of water.
USC-led team adds RNA sequencing data to its massive Parkinson's database; collaboration with Michael J. Fox Foundation could help identify some of the earliest hallmarks of the disease.
Calibr, the drug development division of Scripps Research, announced today that the US Food and Drug Administration (FDA) has cleared its investigational new drug application (IND) for CCW702, a novel immunotherapeutic for the treatment of patients with metastatic castration-resistant prostate cancer. CCW702 has the potential to be effective in patients who have failed prior treatments and have exhausted their treatment options, as it works differently than traditional chemotherapeutics and androgen deprivation therapies.
NeuroCatch Inc., a brain-focused health technology company committed to translating research innovations into real-world medical devices and applications, is pleased to announce a research collaboration in brain vital sign science with Dr. Michael Esser, a pediatric neurologist at the Alberta Children's Hospital, and clinical associate professor at the University of Calgary. This clinical study will use NeuroCatch Inc.'s NeuroCatchTM Platform to study brain function changes in children with mild traumatic brain injuries (mTBI).
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases today announced dosing of the first patient in a Phase 2 study evaluating the safety and efficacy of BT-11 in patients with mild to moderate ulcerative colitis (UC). BT-11 is a novel, orally-administered, gut-restricted, first-in-class therapeutic in clinical development for UC and Crohn's disease (CD).
Scientists at global biopharmaceutical company MSD (Merck in the US) and the Francis Crick Institute have started a unique new collaboration to understand the causes of Motor Neurone Disease and identify potential targets for future treatments.
Some contaminant yeasts make beer bottles and cans explode. VTT scientists developed a genetic test for brewers to detect the strains that cause these problems.